The global peptide antibiotics market was valued at USD 5.35 billion in 2024 and is projected to reach USD 8.97 billion by 2034, registering a CAGR of 5.3% from 2025 to 2034. The global peptide antibiotics market growth is attributed to the increasing prevalence of hospital-acquired infections and bacterial skin infections.
The peptide antibiotics market deals with a short chain of amino acids that has the potential to inhibit or kill the growth of microorganisms such as fungi, bacteria, and viruses by disrupting essential intracellular processes, interfering with cell wall synthesis, and disrupting their cell membranes. These peptides can be synthetically designed in a laboratory and found naturally in various organisms. The increasing prevalence of acute and chronic infectious diseases is expected to drive market growth.
The peptide antibiotics market is witnessing rapid growth due to factors such as rising technological advancements in peptide synthesis, increasing focus on targeted therapies and precision medicine, and increasing growth in new product launches and product approvals. In addition, the growing need for peptide antibiotics in clinics and hospitals and the rise in the cases of antibiotic resistance are further expected to drive the market growth.
Report Coverage | Details |
Market Size in 2025 | USD 5.63 Billion |
Market Size by 2034 | USD 8.97 Billion |
Growth Rate From 2025 to 2034 | CAGR of 5.3% |
Base Year | 2024 |
Forecast Period | 2025-2034 |
Segments Covered | Product, Disease, Route of Administration, Distribution Channels, Region |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
Key Companies Profiled | Pfizer Inc.; Teva Pharmaceuticals Industries Limited; AbbVie Inc.; Merck & Co., Inc.; The Menarini Group; Sanofi; Eli Lilly and Company; GSK plc.; NPS Pharmaceuticals; Xellia Pharmaceuticals. |
Advancements in customized orthodontic treatments create market opportunity
The rising advancements in drug delivery technologies are presenting significant growth opportunities for the market of peptide antibiotics. Researchers are continuously exploring innovative formulations, such as peptide modifications, prodrug strategies, and delivery systems to improve bioavailability, stability, and targeted drug release. In addition, institutional research is substantially invested, with a growing pool of talented technocrats and scientists interested in the arena for innovative therapeutics containing antimicrobial peptides for rare diseases, which may create significant opportunities in the peptide antibiotics market in the coming years.
Limited Commercialization Success may Restrain Market Growth
Leading to uncertainties regarding market success, not all antimicrobial peptides successfully transition from the laboratory to commercial products, despite promising research. In addition, regulatory challenges for the approval of antimicrobial peptides also pose challenges, leading to increased development costs and delays in market entry, which may further be expected to restrain the growth of the peptide antibiotics market.
The non-ribosomal synthesized peptide antibiotics segment dominated the peptide antibiotics market in 2024. The segment growth in the market is attributed to the rising demand for novel therapeutic options, the increasing prevalence of antibiotic resistance, and the increasing unique potential to combat multidrug-resistant pathogens. In addition, the ribosomal synthesized peptide antibiotics segment is expected to grow fastest during the forecast period. The segment growth in the market is driven by rising advancements in genetic engineering and synthetic biology and increasing demand for novel therapeutic approaches to combat antimicrobial infections.
The skin infection segment dominated the peptide antibiotics market in 2024. The segment is witnessing rapid growth in growth due to the increasing incidence rate of cellulitis and the rising prevalence and incidence of skin infections across the globe. Whereas the bloodstream infections segment is expected to grow fastest during the forecast period. The segment growth in the market is contributed by the increasing ability to combat infections, increasing demand for novel antimicrobial solutions, and increasing public health challenges across the globe.
The injectable segment dominated the peptide antibiotics market in 2024. The growing research in the field of peptides, the urgent need for innovative antimicrobial therapies, and rising incidences of multidrug-resistant infections are expected to drive the segment growth. Furthermore, the oral segment is expected to grow fastest during the forecast period. The segment growth in the market is attributed to the increasing demand for patient-friendly and convenient treatment options and rising advances in drug delivery technologies and peptide engineering.
The hospital pharmacies segment dominated the peptide antibiotics market in 2024. The segment plays an important role in the market driven by the critical need for effective antimicrobial therapies in inpatient care industries and the increasing prevalence of multidrug-resistant bacterial infections. Whereas the online pharmacies segment is anticipated to grow fastest during the forecast period. Online pharmacies are offering efficiency and accessibility for both healthcare providers and patients and emerging as a critical distribution channel in the market.
North America dominated the peptide antibiotics market in 2024. The market growth in the region is attributed to the rapid development of advanced peptide therapies, increased collaborations between research institutions and pharmaceutical companies, and rising strong emphasis on technological innovation. The U.S. and Canada are dominating countries driving the market growth.
Asia Pacific Peptide Antibiotics Market Trends
Asia Pacific is expected to grow fastest during the forecast period. The market in the region is witnessing rapid growth due to increased healthcare investments, growing demand for innovative therapeutic solutions, increasing growth in infectious diseases, and growing healthcare and government institutions to recognize the potential of antimicrobial peptides. China, India, Japan, and South Korea are the fastest growing countries in the market.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Peptide Antibiotics Market
By Product
By Disease
Skin Infection
HABP/VABP
Blood Stream Infections
Others
By Distribution Channel
By Regional